Marvel Biosciences is a drug development company with focus on developing new and patent protected drugs using synthetic derivatives of known and approved drugs to target new diseases. MB-204, its lead asset, focuses on the treatment and management of Alzheimer's Disease and Depression.

Company Information

Ticker: MRVL
Exchange: TSXV
Headquarter: Calgary, AB
Shares Outstanding: 39.8 million
Market Cap: $4 million
Insider Ownership: 34.1%

Management Team

Chief Executive Officer: J. Roderick Matheson
- 40 years of experience in capital market and investments formerly at CIBC and Canaccord
- Over $1 billion in financing in public and private biotech companies

Chief Science Officer: Dr. Mark Williams
- 15 years experience in drug development
- Author of 12 patents, inventor of DM199 (in Phase 2 trials for kidney disease/stroke)

Contact Information

Marvel Biosciences Corp.
Tel: 403-770-2469
Email: info@marvelbiosciences.com

The Problem

Dementia Incidence by Age

Source: 2022 Alzheimer's Association, Alzheimer's & Dementia Vol 18, Issue 4, April 2022, 545-868

Shift in the Global Demographic

Alzheimer's Disease
- 57M patients 2019
- 153M by 2050

Source: United Nations, http://esa.un.org/wpp/population-pyramids/population-pyramids_absolute.htm

- **40%** of AD patients suffer from Depression
- AD Market to grow to **$25 Billion** by 2029

The Solution

MB-204 is a synthetic derivative of Istradefylline, an off-patent FDA-approved Parkinson's Disease drug. MB-204 is designed to treat and manage depression and Alzheimer's Disease (AD) by targeting A2A receptors, known to be a credible target and clinical interest in treatment of AD and related disorders. MB-204 is expected to enter Phase 1 human trials in Q1 2024.

MB-204 compared to Istradefylline is
- **longer lasting**
- **shows higher reduction in depression symptoms**
- **lowers anxiety symptoms**

Comparable Companies in Similar Stages of Development ($CAD)

ProMIS™ Neurosciences $22M*   NervGen Pharma $120M*

Pre-Clinical done → Toxicology → Phase 1 → Phase 1 b

Marvel Milestones   Q3 2023 $4M CAD*   Q4 2023

MARVEL BIOSCIENCES CORP.

Why Invest?

- MB-204 – A potential solution to a growing Alzheimer's and Depression market
- Comparable companies valued at ~$20 - 100M at a similar toxicology stage compared to Marvel Biosciences' (valued at $4M)
- Entering Phase 1 human trials by Q1 2024– Comparable valuations of >$100M

Marvel will be in a position to review opportunities with larger pharmaceutical companies before Phase 2